276. Achondroplasia Clinical trials / Disease details

Clinical trials : 51 / Drugs : 34 - (DrugBank : 6) / Drug target genes : 4 - Drug target pathways : 26

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2017-000701-21-DE (EUCTR)	19/06/2017	27/04/2017	A study looking at growth measurements of children with achondroplasia	A Multicenter, Multinational Clinical Assessment Study for PediatricPatients with Achondroplasia	Achondroplasia MedDRA version: 20.0;Level: LLT;Classification code 10000452;Term: Achondroplasia;System Organ Class: 100000004850;Therapeutic area: Body processes [G] - Bones and nerves physological processes [G11]	INN or Proposed INN: vorsoritide	BioMarin Pharmaceutical Inc.	NULL	Not Recruiting			Female: yes Male: yes	500	Phase 1	France;United States;Spain;Turkey;Australia;Germany;United Kingdom;Japan
2	EUCTR2015-003836-11-ES (EUCTR)	19/04/2017	10/03/2017	A Phase 3 Study to Evaluate the Safety and Efficacy of BMN 111 in Children with Achondroplasia	A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of BMN 111 in Children with Achondroplasia. -	achondroplasia MedDRA version: 19.1;Level: LLT;Classification code 10000452;Term: Achondroplasia;System Organ Class: 100000004850;Therapeutic area: Body processes [G] - Bones and nerves physological processes [G11]	Product Name: modified recombinant human C-type natriuretic peptide Product Code: BMN 111 INN or Proposed INN: vorsoritide Other descriptive name: MODIFIED RHCNP	BioMarin Pharmaceutical Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	110	Phase 3	France;United States;Spain;Turkey;Australia;Germany;Japan;United Kingdom